Gary Cohan
Internal Medicine · Beverly Hills, CANPI 1952450769
Payments from drug & device makers
Across 221 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$795
- Gilead$693
- Amgen$676
- Daiichi Sankyo Inc.$402
- Novartis$301
- Merck$199
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 48 | $795 |
| Gilead | 42 | $693 |
| Amgen(2 entities) | 34 | $676 |
| Daiichi Sankyo Inc. | 16 | $402 |
| Novartis | 13 | $301 |
| Merck | 7 | $199 |
| Lilly USA, LLC | 8 | $183 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $167 |
| Dexcom, Inc. | 6 | $157 |
| Boston Scientific | 3 | $95 |
| AbbVie(2 entities) | 4 | $89 |
| AstraZeneca | 5 | $83 |
| GSK | 3 | $68 |
| Exact Sciences | 3 | $66 |
| Heartflow, Inc. | 3 | $64 |
| Novo Nordisk | 3 | $54 |
| Abbott | 2 | $47 |
| Pfizer | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Genentech USA, Inc. | 2 | $34 |
| EMD Serono, Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $18 |
| Mannkind Corporation | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
How this compares
$4,391 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 109 | $452,142 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $172,633 |
| DovatoDolutegravir Sodium/Lamivudine | 23 | $75,929 |
| MounjaroTirzepatide | 34 | $41,100 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,131 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,697 |
| OzempicSemaglutide | 18 | $16,480 |
| EliquisApixaban | 15 | $12,619 |
| Repatha SureclickEvolocumab | 16 | $8,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,176 |
| Testosterone | 54 | $7,860 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,104 |
| Rosuvastatin Calcium | 131 | $2,363 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 14 | $2,281 |
| Eszopiclone | 22 | $2,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Dovato | $795 | $528,071132 claims |
| GileadBiktarvy, Descovy | $693 | $198,33058 claims |
| Lilly USA, LLCMounjaro | $183 | $41,10034 claims |
| Novo NordiskOzempic | $54 | $16,48018 claims |
| PfizerEliquis | $44 | $12,61915 claims |
| GSKTrelegy Ellipta | $68 | $8,17614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $44 | $5,10411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Beverly Hills
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.